A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe
Objectives: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Kalydeco® (ivacaftor), Orkambi® (lumacaftor/ivacaftor) and Symkevi® (tezacaftor/ivacaftor), have substantially improved patients’ lives yet significantly burden healthcare budgets. This analysis aims to compare pricin...
Guardado en:
Autores principales: | Khadidja Abdallah, Kris De Boeck, Marc Dooms, Steven Simoens |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/54c83bf9580b4210b5f605462054c3aa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Obesity in cystic fibrosis
por: Katherine A. Kutney, et al.
Publicado: (2021) -
Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
por: Schmidt BZ, et al.
Publicado: (2016) - Journal of cystic fibrosis
-
Editorial: Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
por: Carla Maria Pedrosa Ribeiro, et al.
Publicado: (2021) -
Liver disease in cystic fibrosis
por: Tombazzi,Claudio R, et al.
Publicado: (2001)